PDCD1 and neoplasm: Given that the immune mechanism is related to the kynurenine pathway and kynurenine to tryptophan ratio, it contributed to the development of a marker of tumor aggressiveness and metabolic profiling alteration in response to treatment with PD-1 inhibitors (e.g., nivolumab and pembrolizumab).